Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults

Liu, Jiaye; Ayada, Ibrahim; Zhang, Xiaofang; Wang, Ling; Yang, Li; Wen, Tianfu; Ma, Zhiyong; Bruno, Marco J.; Knegt, Robert J. de; Cao, Wanlu; Peppelenbosch, Maikel P.; Ghanbari, Mohsen; Li, Zhihui; Pan, Qiuwei

doi:10.1016/j.cgh.2021.02.030

Cited by 117 publications

(111 citation statements)

References 32 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recently published systematic review and meta-analysis showed that the estimated global prevalence of MAFLD in overweight and obese adults was 50.7%, with a higher prevalence in men (59.0%) than women (47.5%) [ 51 ]. The pooled estimated prevalence of comorbidities was 19.7% and 57.5% for T2DM and metabolic syndrome, respectively [ 51 ].…”

Section: The Evidence To Support the Change In Terminology From Nafld To Mafldmentioning

confidence: 99%

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Méndez-Sánchez

Díaz-Orozco

2021

Med Sci Monit

View full text Add to dashboard Cite

In 2020, international consensus guidelines recommended the renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), supported by diagnostic criteria. MAFLD affects up to 25% of the global population. However, the rates of MAFLD are likely to be underestimated due to the increasing prevalence of type 2 diabetes mellitus (T2DM) and obesity. Within the next decade, MAFLD has been projected to become a major cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide, as well as the most common indication for liver transplantation in the US. This transition in terminology and clinical criteria may increase momentum and clinical evidence at multiple levels, including patient diagnosis, management, and care, and provide the basis for new research areas and clinical development for therapeutics. The diagnostic criteria for MAFLD are practical, simple, and superior to the existing NAFLD criteria for identifying patients at increased risk of developing progressive liver disease. This Editorial aims to present the historical evolution of the terminology for fatty liver disease and the advantages of diagnosis, patient management, and future research on MAFLD.

show abstract

Section: The Evidence To Support the Change In Terminology From Nafld To Mafldmentioning

confidence: 99%

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Méndez-Sánchez

Díaz-Orozco

2021

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…(2021 г. ), обобщивший результаты 116 исследований (n=2 667 052), показал, что глобальная распространенность НАЖБП у взрослых лиц с избыточной массой тела и ожирением составляет 50,7% (95% ДИ 46,9-54,4) [58]. Согласно метаанализу L. Li и соавт.…”

Section: заболевания печениunclassified

Obesity as a risk factor for diseases of the digestive system

Andreev

Николаевич²,

Kucheryavy³

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Currently, the global prevalence of obesity among the worlds adult population is about 650 million people, which makes it possible to consider this chronic metabolic disease as a non-infectious pandemic of the 21st century. It has been proven that obesity is associated with several gastroenterological diseases, while the mechanisms of these associations are extremely heterogeneous and multifactorial. Hypertrophy and hyperplasia of adipocytes in obesity lead to a change in the profile of adipokine production (a decrease in adiponectin, an increase in leptin), an increase in the production of pro-inflammatory cytokines (interleukin-1, 6, 8, tumor necrosis factor ), C-reactive protein, free fatty acids, as well as active forms of oxygen (superoxide radicals, H2O2). All the above induces the development of chronic slowly progressive inflammation, oxidative stress, and insulin resistance. In addition, peptides secreted by adipocytes (adiponectin, leptin, nesfatin-1 and apelin) can modulate gastrointestinal motility, acting both centrally and peripherally. The qualitative and quantitative changes in the intestinal microbiota observed in obese patients (increased Firmicutes and decreased Bacteroidetes) lead to a decrease in the production of short-chain fatty acids and an increase in the intestinal permeability due to disruption of intercellular tight junctions, which leads to increased translocation of bacteria and endotoxins into the systemic circulation. Numerous studies have demonstrated the association of obesity with diseases of the esophagus (gastroesophageal reflux disease, Barretts esophagus, esophageal adenocarcinoma, esophageal motility disorders), stomach (functional dyspepsia, stomach cancer), gallbladder (cholelithiasis, gallbladder cancer), pancreas (acute pancreatitis, pancreatic cancer), liver (non-alcoholic fatty liver disease, hepatocellular carcinoma), intestine (diverticular disease, irritable bowel syndrome, colorectal cancer).

show abstract

“…Recently, a new definition was suggested for NAFLD, namely metabolic dysfunction-associated fatty liver disease (MAFLD) [ 2 ]. The prevalence of MAFLD among obese adults worldwide is 50.7%, with 95% CI 46.9–54.4 [ 3 ], relatively higher in men (59.0%, 95% CI 52.0–65.6) than women (47.5%, 95% CI 40.7–54.5). NAFLD is tightly associated with obesity, diabetes, and metabolic syndromes [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Current Options and Future Directions for NAFLD and NASH Treatment

Zhang

Yang

2021

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of nonalcoholic steatohepatitis (NASH). Although there are many undergoing clinical trials for NAFLD treatment, there is no currently approved treatment. NAFLD accounts as a major causing factor for the development of hepatocellular carcinoma (HCC), and its incidence rises accompanying the prevalence of obesity and diabetes. Reprogramming of antidiabetic and anti-obesity medicine is a major treatment option for NAFLD and NASH. Liver inflammation and cellular death, with or without fibrosis account for the progression of NAFLD to NASH. Therefore, molecules and signaling pathways involved in hepatic inflammation, fibrosis, and cell death are critically important targets for the therapy of NAFLD and NASH. In addition, the avoidance of aberrant infiltration of inflammatory cytokines by treating with CCR antagonists also provides a therapeutic option. Currently, there is an increasing number of pre-clinical and clinical trials undergoing to evaluate the effects of antidiabetic and anti-obesity drugs, antibiotics, pan-caspase inhibitors, CCR2/5 antagonists, and others on NAFLD, NASH, and liver fibrosis. Non-invasive serum diagnostic markers are developed for fulfilling the need of diagnostic testing in a large amount of NAFLD cases. Overall, a better understanding of the underlying mechanism of the pathogenesis of NAFLD is helpful to choose an optimized treatment.

show abstract

Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults

Cited by 117 publications

References 32 publications

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)

Obesity as a risk factor for diseases of the digestive system

Current Options and Future Directions for NAFLD and NASH Treatment

Contact Info

Product

Resources

About